G. Hovingh

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial

H. Colhoun, I. Lingvay, D. Dicker, 2024, Nature medicine.

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

D. Kitzman, V. Melenovský, D. Lewinski, 2024, The Lancet.

Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial

N. Poulter, D. McGuire, J. Buse, 2023, Diabetes, obesity & metabolism.

Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics

G. Hovingh, A. Lincoff, S. Kahn, 2022, Obesity.

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

John E. Poremba, H. Randeva, P. Borne, 2024, The Lancet.

Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design.

G. Hovingh, A. Lincoff, S. Kahn, 2020, American heart journal.

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

I. Lingvay, K. Brown-Frandsen, Steven E. Kahn, 2023, The New England journal of medicine.